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Objectives The aim of this study was to test the hypothesis that mitral valve (MV) enlargement occurring in chronic aortic
regurgitation (AR) prevents functional mitral regurgitation (FMR).
Background Chronic AR causes left ventricular (LV) dilation, creating the potential for FMR. However, FMR is typically absent
during compensated AR despite substantial LV enlargement. Increased mitral leaflet area has been identified in
AR, but it is unknown whether increased MV size can represent a compensatory mechanism capable of prevent-
ing FMR.
Methods Database review of 816 patients with at least moderate AR evaluated the prevalence of FMR. A total of 90 pa-
tients were enrolled prospectively for 3-dimensional echocardiography (30 AR, 30 FMR, and 30 controls) to as-
sess MV geometry including total leaflet area.
Results FMR was present in 5.6% of AR patients by database review. Prospectively, only 1 AR patient had more than
mild FMR despite increased LV end-diastolic volume (82  22, 86  23, and 51  12 cm3/m2, respectively, for
AR, FMR vs. control patients; p  0.01) and similar sphericity index, annular area, and tethering distances com-
pared with FMR. Total MV area was largest in AR (31.3% greater than normal), increasing significantly more
than in FMR. The ratio of valve size to closure area was maintained in AR, whereas decreases in this ratio and
LV ejection fraction independently predicted FMR.
Conclusions FMR prevalence is low in chronic AR. MV leaflet area is significantly increased compared with control and FMR
patients, preserving a normal relationship to the area needed for closure in the dilated LV. Understanding
the mechanisms underlying this adaptation could lead to new therapeutic interventions to prevent FMR.
(J Am Coll Cardiol 2013;61:1809–16) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.064Functional mitral regurgitation (MR) is a common compli-
cation of cardiomyopathies associated with higher mortality
(1–4). Its mechanisms have been related to left ventricular
(LV) enlargement and distorted shape, restricting mitral
valve (MV) closure (5–8). However, LV remodeling alone
fails to explain why MR severity varies among individuals
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2013, accepted January 21, 2013.with similar degrees of tethering (9). Recent evidence
showed that MV leaflets can enlarge in response to LV
morphological changes (9–12), with the potential to reduce
MR (10). Experimentally, mechanical stretch can promote
See page 1817
adaptive MV growth (11), but little is known about the
clinical implications of this phenomenon. A naturally oc-
curring setting in which MV adaptation can be studied is in
patients with chronic aortic regurgitation (AR), in whom
functional MR is infrequent (13,14) despite often severe LV
dilation (6,8,13–21). This absence of MR challenges the
concept linking functional MR (FMR) solely to LV remod-
eling. Interestingly, necropsy data previously demonstrated
MV enlargement in chronic AR (22), but this finding has
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determinants in vivo. Whether
this phenomenon can be seen as
an adaptation counterbalancing LV
dilation to prevent MR is unknown.
We tested the hypothesis that
MV enlargement occurs in chronic
AR and preserves normal mitral
geometry relative to the dilated left
ventricle to prevent MR. We first
assessed FMR prevalence in
chronic AR by database review.
We then prospectively enrolled patients for 3-dimensional
(3D) echocardiography to assess MV size and its relation with
LV geometry and function in patients with either chronic AR
or MR (ischemic or nonischemic) and in normal control
patients using recently developed capabilities for measuring
MV area noninvasively (10).
Methods
Retrospective analysis. To assess the prevalence of MR in
atients with AR, we searched our institutional echocardio-
raphic database for patients older than 18 years of age with
oderate or severe AR who had a transthoracic echocar-
iogram within the past 5 years. Exclusion criteria were
ore than mild systolic dysfunction (left ventricular ejection
raction [LVEF] 40%), LV regional wall motion abnor-
ality, severe aortic stenosis (valve area 1.0 cm2), MV
rganic pathology (prolapse, rheumatic disease, mitral cleft,
ndocarditis, and extensive annular calcification), presence
f an aortic or mitral prosthesis, and Marfan syndrome. In
ll patients having more than mild MR, the echocardio-
raphic images were reviewed to confirm the presence of
MR.
rospective recruitment. From January 2011 to June
012, we prospectively enrolled 90 subjects for 3D echocar-
iography: 30 consecutive patients who had at least mod-
rate AR without any previously stated exclusion criteria, 30
atients with moderate or severe FMR (ischemic or non-
schemic) and LV end-diastolic dimension comparable to
he AR group, and 30 normal control patients (age and sex
omparable to AR group) with normal echocardiograms and
ithout known cardiac disease (patients with treated hyper-
ension and no evident LV hypertrophy were not excluded).
R severity was assessed with an integrative approach using
olor Doppler (vena contracta), regurgitant volume and
raction, and assessment of flow reversal in the descending
orta (23). MR was graded as trace, mild, moderate, or
evere integrating color Doppler jet area and vena contracta
idth (23–25). Medical records were consulted to assess the
ause and known duration of AR. All patients gave in-
ormed consent before enrollment. The study was approved
y the hospital’s institutional review board.
chocardiography. All prospectively enrolled patients un-
Abbreviations
and Acronyms
3D  3-dimensional
AR  aortic regurgitation
FMR  functional mitral
regurgitation
LV  left ventricular
MR  mitral regurgitation
MV  mitral valveerwent standard transthoracic echocardiography using ahilips iE33 scanner with a 5-MHz transducer (Philips
ealthcare, Andover, Massachusetts). Full-volume 3D da-
asets were obtained from the apical window using an X3
atrix-array transducer. The analysis was performed by a
ingle observer using QLAB 5.1 (Philips Healthcare) and
ustom software for MV area and tethering geometry
Omni 4D, M.D.H.). The 3D datasets were analyzed
eparately and blinded to the presence and severity of AR
nd MR. The 3D LV end-diastolic and end-systolic vol-
mes were measured. LV sphericity was evaluated by the
atio of short-axis diameter/long-axis length at end-diastole
nd end-systole (8,26). Midsystolic (identified by frame
ount) tethering distances from papillary muscle tips to
ontralateral annulus (26) were measured from the 3D
ataset. Midsystolic mitral annular area was calculated as
he projection of the annular trace onto its average or
east-squares plane. Total mitral leaflet area was measured in
iastole (Fig. 1) using a previously described and validated
ethod that integrates valve area traced from the 3D dataset
10). Closure area was defined as the closed leaflet surface
etween the LV and left atrium in mid-systole, and thus
epresents the minimal area that needs to be covered by the
eaflets to occlude the mitral orifice. The ratios of total
eaflet to annular area and of total leaflet area to closure area
ere calculated to assess the adequacy of leaflet adaptation
elative to LV and annular changes. Dimensions, areas, and
olumes were indexed for body surface area. MV thickness
as measured in the 2-dimensional echocardiography data-
ets in the parasternal long-axis view in a diastolic frame
ithout rapid motion with the leaflets as perpendicular as
ossible to the echocardiographic beam to take advantage of
ts axial resolution (27–29). As FMR can be related to
ecreased closing forces in a failing ventricle (30,31), we also
easured key parameters of LV contractility including 3D
alculated LVEF, end-systolic wall stress reflecting after-
oad (32,33), and end-systolic volume index, which is
elatively preload independent. In the absence of
ontinuous-wave Doppler in the patients without MR to
rovide true transmitral pressure, mitral closing forces were
stimated as: force (N)  0.0133 · systolic arterial pressure
(mm Hg) · leaflet area (cm2).
Statistics. Continuous variables are expressed as mean 
SD and categorical variables as number (percentage). Dif-
ferences in proportions were assessed by the chi-square test.
Logistic univariate and multivariate regressions were used to
assess the predictors of significant MR in the database
population. Age, sex, LVEF, and LV end-diastolic and
end-systolic dimensions were included in the model. In the
prospectively recruited population, echocardiographic vari-
ables of the AR group were compared with those of the
FMR and control groups. Differences in means among the
3 groups were assessed by 1-way analysis of variance with
Bonferroni multiple-comparison tests. We assessed the
differential relationship of mitral leaflet area and LV end-
diastolic volume by linear regression including group (AR or
FMR) as an interaction term. Known AR duration and
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April 30, 2013:1809–16 Mitral Valve Enlargement in Aortic Regurgitationleaflet area in the AR group was also assessed with linear
regressions. Leaflet thickness and area were compared
among patients with AR jets that were central versus
posteriorly directed onto the anterior mitral leaflet. Multi-
variate logistic regression was used to assess the relationship
of total leaflet to closure area ratio and the presence of MR,
including in the model variables describing LV function
that were significant among FMR and AR patients by
univariate analysis: LVEF, end-systolic wall stress, and
end-systolic volume index. Regression coefficients standard-
ized for SD were computed. Statistical analysis was per-
formed with Stata/IC 11.2 (StataCorp LP, College Station,
Texas).
Results
Retrospective review. We identified a total of 816 patients
with moderate or severe AR (Table 1). Moderate or severe
FMR was found in 46 patients (5.6%). Age (p  0.01),
LVEF (p  0.01), LV end-diastolic (p  0.01), and
end-systolic dimensions (p  0.01) were significant predic-
tors of MR. On multivariate analysis, age (p  0.01), sex
(p  0.01), and LV end-diastolic dimension (p  0.02)
were significant.
Prospective study. A total of 90 patients were enrolled (30
patients with AR, 30 patients with FMR, and 30 normal
Figure 1 Mitral Valve Reconstruction for Total Leaflet Area Me
Sequential leaflet tracing in multiple planes allows computation of total mitral leafl
of leaflet coaptation cannot be uniformly visualized [10]). LA  left atrium; LV  lecontrol patients); their characteristics are shown in Table 2. dauses of AR were endocarditis (5 patients, with infection
esolved medically), congenital aortic valve disease (n 21),
nd aortic root dilation (n  4), and the median known AR
uration was 24 months (range, 1 month to 10 years). The
R and control groups were not significantly different in
ge, sex, body surface area, or comorbidities (hypertension
nd diabetes); more of the AR patients were treated with
enin-angiotensin system blockers for afterload reduction
ompared with control patients (57% vs. 27%, p  0.04).
nly 1 patient in the AR group had more than mild
moderate to severe) MR, with LV enlargement, mild
lobal dysfunction, and incomplete mitral leaflet closure.
MR patients were similar in sex, but older than control
atients and AR patients. The FMR group mostly consisted
ment Using 3-Dimensional Echocardiography
a (measurable clearly only in diastole because the systolic areas
tricle.
Echocardiographic Characteristics ofModer te to Severe Ao tic Regurgitation PatientsTable 1 Echo ardi graph c Char cteristics ofModerate to Severe Aortic Regurgitation Patients
Total Population
(N  816)
MR
(n  46)
No MR
(n  770) p Value
Age, yrs 64 18 72 14 63 18 0.01
Males 499 (61) 22 (48) 477 (62) 0.06
LVEF, % 64 9 61 11 65 8 0.01
LVIDed, mm 49 8 52 8 49 8 0.01
LVIDes, mm 32 7 36 8 32 7 0.01
Values are mean  SD or n (%).asure
et are
ft venLVEF  left ventricular ejection fraction; LVIDed  left ventricular internal diameter at end-
iastole; LVIDes  left ventricular internal diameter at end-systole; MR  mitral regurgitation.
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Mitral Valve Enlargement in Aortic Regurgitation April 30, 2013:1809–16of patients with ischemic cardiomyopathy (25 ischemic, 5
nonischemic), and none of these patients had more than
mild AR.
AR and FMR patients had a comparable increase in LV
volumes compared with control patients (end-diastolic vol-
ume index: 82 22 vs. 86 23 vs. 51 12 cm3/m2 for the
R, FMR, and control groups; p  0.01). Also, LV
phericity index, tethering distances, annulus area, and
losure area were all similarly increased in the AR and FMR
roups compared with control patients. End-systolic wall
tress was significantly increased in FMR compared with
R and control patients, consistent with increased after-
oad, and comparable to the results of Reichek et al. (32).
itral closing force was increased in both FMR and AR
roups compared with control patients, driven by increased
eaflet and annular area. The 3D MV closure area, annulus
rea, and total leaflet area are shown in Table 2 and Figure 2.
otal mitral leaflet area was the largest in AR patients
31.3% larger than normal, 16.8  3.7 cm2 vs. 12.8  2.3
cm2 for controls, p  0.01), with comparable differences
ersisting when normalized to body surface area. There was
significant relationship between valve size and AR regur-
itant volume (p  0.01). Although FMR patients also had
ome degree of valve enlargement, the magnitude was
ignificantly less than in AR patients (Table 2). The ratio of
otal leaflet area to systolic closure area was preserved in the
R group and identical to that of control patients (1.4 
Echocardiographic Characteristics of Aortic RegFunctional Mitral Regu gitation, and Con rol PaTable 2 Echo ardio raph c CharacteristicsFunctional Mitral Regurgitation, an
Characteristics (n
Age, yrs 47
Males 2
Body surface area, m2 1.9
MR more than mild
LVEDV, cm3 154
LVEDV index, cm3/m2 82
LVESV, cm3 62
LVESV index, cm3/m2 33
LVEF, % 61
Diastolic sphericity ratio, D/L 0.52
Systolic sphericity ratio, D/L 0.44
Midsystolic tethering distance, medial PM, mm 43
Midsystolic tethering distance, lateral PM, mm 42
Leaflet area, cm2 16.8
Leaflet area index, cm2/m2 8.9
Midsystolic closure area, cm2 12.1
Midsystolic annulus area, cm2 9.9
Leaflet area/closure area ratio 1.4
Leaflet area/annulus area ratio 1.7
End-systolic wall stress, 103 dyn/cm2 83
Closing force, N 28.0
Values are mean  SD or n (%). *p  0.05 versus FMR group. †p  0
AR aortic regurgitation; D left ventricular short-axis diameter; FM
LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular
regurgitation; PM  papillary muscle..2 in both groups, p  0.26), indicating adequate leafletompensation for the increased area requirements de-
anded by the dilated LV. In contrast, this ratio was
ignificantly decreased in FMR patients (1.2  0.1, p 
.01 vs. control and AR groups), indicating a relatively
ation,rtic Regurgitation,
trol Patients
Normal
(n  30)
FMR
(n  30) p Value
45 17 69 14† 0.01
15 (50) 18 (60) 0.20
1.8 0.2 1.9 0.2 0.06
0 (0) 30 (100) 0.01
92 23 167 52† 0.01
51 12 86 23† 0.01
† 33 12 106 44† 0.01
† 18 7 55 20† 0.01
64 7 37 11† 0.01
7† 0.44 0.05 0.52 0.05† 0.01
6† 0.36 0.07 0.47 0.06† 0.01
38 4 41 6 0.01
36 5 39 5 0.01
† 12.8 2.3 15.4 2.7† 0.01
*† 7.1 1.3 8.0 1.4 0.01
† 9.7 1.9 12.6 2.0† 0.01
† 8.2 1.6 10.0 1.5† 0.01
* 1.4 0.2 1.2 0.1† 0.01
* 1.6 0.2 1.5 0.2 0.01
71 23 135 48† 0.01
† 20.3 3.9 25.3 6.1† 0.01
rsus control group.
nctional mitral regurgitation; L left ventricular long-axis dimension;
n fraction; LVESV  left ventricular end-systolic volume; MR  mitral
Figure 2
Total Leaflet Area, Midsystolic Closure, and Annulus
Areas in Control, Functional Mitral Regurgitation,
and Aortic Regurgitation Patients
The midsystolic closure and annulus areas are both similarly increased in aor-
tic regurgitation (AR) and functional mitral regurgitation (MR) patients compared
with control patients. In AR, there is a proportional increase in total valve area,
maintaining a normal relationship between valve and left ventricular sizes
(manifested by a normal ratio of total leaflet area to closure area), which is not
the case in patients with functional MR.urgittientsof Ao
d Con
AR
 30)
 17*
2 (73)
 0.2
1 (3)
 46†
 22†
 25*
 13*
 7*
 0.0
 0.0
 7†
 7†
 3.7
 1.6
 2.8
 2.2
 0.2
 0.2
 23*
 8.6
.05 ve
R fu
t
1
2
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There was no significant relationship between age and
leaflet to closure area ratio in any studied group or the
overall population (p  0.20). The ratio of total leaflet area
o annulus area showed the same pattern (1.7  0.2 vs.
.5  0.2 vs. 1.6  0.2 for AR, FMR, and controls; p 
0.01 between AR and FMR) with a preserved ratio in AR
patients and a reduced one in FMR patients. Patients with
AR and FMR also had increased mitral leaflet thickness
compared with controls (2.4 0.3 mm vs. 2.5 0.6 mm vs.
.1  0.4 mm for AR, FMR, and control patients; p 
0.01). An example of increased 3D leaflet area in a patient
with severe AR and a dilated left ventricle but only trace
MR versus a control patient with comparable age and body
surface area is shown in Figure 3.
In both the AR and FMR groups, there was a significant
linear relationship between MV leaflet area and LV end-
diastolic volume. However, the magnitude of valve enlarge-
ment relative to LV size was greater in AR patients (Fig. 4)
(p 0.004 between FMR and AR groups). Twenty-one of the
30 AR patients had the regurgitant jet posteriorly directed onto
Figure 3 Example of Mitral Valve Enlargement in Aortic Regurg
Representative example showing 3-dimensional reconstructions of control and chr
severe aortic regurgitation (A), a dilated left ventricle at 6.8 cm (B), and only trac
struction of the mitral leaflets showing increased annulus size and larger leaflet a
surface area. LV  left ventricular.the anterior mitral leaflet, but without any difference in mitral sleaflet area or thickness compared with those with central jets
(leaflet area, 8.8 cm2/m2 vs. 9.0 cm2/m2; p  0.86; anterior
thickness, 2.5  0.3 mm vs. 2.4  0.5 mm; p  0.76). There
was no effect of known AR time duration on the degree of MV
enlargement (p  0.45). A subset of 5 patients had a history
of aortic valve endocarditis and sudden onset of moderate to
severe AR. These patients were not significantly different
from other AR patients with regard to LV volume and MV
leaflet area in the chronic compensated state studied by 3D
echocardiography.
Multivariate predictors of MR. Table 2 presents a uni-
variate comparison of means between the AR, FMR, and
control groups. LVEF, end-systolic wall stress, and end-
systolic volume index were significantly different in the AR
group compared with the FMR group, and these differences
could affect MR severity. In a multivariate analysis control-
ling for those variables, the ratio of total leaflet/closure area
remained significantly associated with the presence of MR
(standardized regression coefficient of 0.07, p  0.029)
along with LVEF (standardized regression coefficient of 0.04,
p  0.025); end-systolic volume index and end-systolic wall
n
rtic regurgitation patients. Top row: Transthoracic echocardiogram showing
l regurgitation (C). Middle row: Different projections of a 3-dimensional recon-
ttom row: Same reconstruction in a control patient matched for age and bodyitatio
onic ao
e mitra
rea. Botress had p values of 0.057 and 0.098, respectively.
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The results of this study show that despite an enlarged left
ventricle, increased sphericity, longer tethering distance, and
a dilated mitral annulus, patients with chronic compensated
AR have a surprisingly low incidence of FMR. Although
the absence of MR is consistent with the usually slow
clinical evolution of chronic compensated AR, this obser-
vation challenges the current concepts relating FMR solely
to LV remodeling. A 3D reconstruction of the MV valve
showed that AR patients have a compensatory increase
30% in their mitral leaflet area, which remains propor-
tional to the LV volume and the demands it imposes in
terms of mitral systolic closure area. Interestingly, the AR
group also had slightly thicker mitral leaflets, suggesting
that enlargement is not due to passive stretch alone and
raising the possibility of active growth of cells, matrix, or
both. In contrast, patients with FMR had a proportionally
smaller valve increase despite similar LV size, sphericity
index, and tethering distances, suggesting possible factors
that can limit or favor MV growth depending on the
underlying pathophysiology. The ratio of total leaflet area to
the area required for leaflet closure, a strong determinant of
MR (10), was also preserved in AR and reduced in FMR.
Valve area increased more steeply with increasing LV
end-diastolic volume in AR versus FMR. These results are
in accordance with the necropsy data of Mautner et al. (22)
that showed increased MV area and mass in AR, and add to
Figure 4
Relationship Between Total Leaflet Area and Left
Ventricular Volume in Aortic Regurgitation and
Patients With Functional Mitral Regurgitation
In both groups, there is a linear relationship between mitral valve size and left
ventricular (LV) volume. The increase in valve size is, however, greater in
patients with aortic regurgitation (AR) compared with those with functional
mitral regurgitation (FMR). MR  mitral regurgitation.the observations of relatively lesser increases in MV area inFMR, with a decreased ratio of total to closure leaflet areas.
Of note, the absolute valve areas obtained in our study are
greater than those reported by necropsy, which may relate to
different measurement methods. In the necropsy study, the
leaflets were formalin fixed and excised 2 to 3 mm caudal to
the annulus, which, when spread over the entire annulus,
can make a substantial difference in total area. The relative
increase in area compared with the control group was
similar in both studies.
These results add to the growing literature suggesting
that valve leaflets are able to remodel and adapt in response
to LV morphological changes rather than being only passive
flaps. Interestingly, increased aortic leaflet dimensions have
also been reported in patients with AR and aortic root
dilation, suggesting aortic valve adaptation (34). Insights
from recent animal studies suggest that MV mechanical
stretch can induce valve growth (11) by reactivating embry-
onic development pathways, also shown with mechanical
stretch of in vitro valve constructs (35). Of note, the same in
vivo study showed significant valve enlargement after only
60 days of mechanical stretch. This is consistent with our
subset of patients having shorter AR evolution but the same
degree of valve enlargement in the chronic state of LV
dilation. Although mechanical stretch is likely involved,
other potential mechanisms may also stimulate valve
growth. It has been shown that LV eccentric hypertrophy in
AR is the result of numerous extracellular matrix genes
being modulated in the myocardium (36), and expression of
these genes is also modified in MR-induced volume over-
load (37). It is possible that MV tissue shares some of these
molecular remodeling mechanisms present in the LV myo-
cardium, which could promote valve enlargement in parallel
with LV dilation. Interestingly, a previous animal study of
LV pressure overload was associated with not only MV but
also tricuspid valve changes, leading the authors to suggest
the possibility of circulating factors inducing valve remod-
eling (38).
Implication for FMR. We demonstrate here that the
compensated chronic AR population shows adequate mitral
leaflet adaptation, even with severe LV dilation. In addition
to disturbed ventricular geometry, FMR is the result of an
imbalance between closing and tethering forces (30,31).
Importantly, a larger valve and annulus not only provide
more tissue to cover the increased closure area, but also
contribute to greater closing forces (proportional to area). In
the multivariate analysis, the leaflet-to-closure area ratio was
a strong predictor of FMR, independent of LVEF, systolic
wall stress, and LV end-systolic volume index. Decreased
LVEF, which reflects the underlying cardiac pathology but
also the additional remodeling imposed by the presence of
MR, was also significant. The presence of MR therefore
depends on both leaflet enlargement and LV contractility.
This adaptation is, however, inadequate in patients with
FMR (less valve enlargement despite comparable LV size),
which remains common in ischemic and myopathic heart
failure. It will therefore be relevant in future work to
g1815JACC Vol. 61, No. 17, 2013 Beaudoin et al.
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these patients. Interestingly, although valve enlargement
can promote mitral coaptation, other results have suggested
that leaflet remodeling can potentially induce maladaptive
valve stiffness and fibrosis, interfering with valve function
(39–41). This suggests that mitral leaflet remodeling could
be a double-edged sword, preventing MR in certain situa-
tions, but with the potential to contribute to MR in other
cases. One major difference between our chronic stable AR
population and other ischemic or nonischemic cardiomyop-
athies is the preserved systolic function and the absence of
clinical heart failure. Heart failure is associated with strong
humoral and proinflammatory cytokine activation, factors
well known to induce and modify remodeling in the LV and
numerous other organs. Although renin-angiotensin and
adrenergic systems are also activated in chronic AR (42,43),
the magnitude of this activation in asymptomatic patients
with preserved function is likely lower than what is seen in
the setting of ischemic and nonischemic systolic dysfunc-
tion. It is currently unknown whether this exaggerated
humoral activation can modify valve leaflet growth, al-
though the profibrotic effects of angiotensin are well de-
scribed (44,45). Future mechanistic studies are warranted to
explore the factors potentially limiting leaflet growth and
flexible closure because they could eventually represent
future therapeutic targets.
Study limitations. The observed increases in leaflet area
and thickness suggest possible cellular growth activation,
but no biological samples were available in this imaging
study. Our study shows that compensated AR is associated
with adequate MV adaptation, but the biological mecha-
nisms leading to valve growth need to be explored. We are
currently planning additional studies looking at valve area over
time in chronic AR, acute AR, and the transition to decom-
pensated heart failure, in which clinical experience indicates
that FMR is more common. Also, the influence of other
variables such as age, medication, and comorbidities on MV
adaptation and incidence of FMR in various populations
(ischemic and nonischemic heart failure) needs to be assessed
in clinical studies designed to address those influences.
Conclusions
Patients with chronic, clinically stable moderate to severe
AR have a large increase in mitral leaflet size. This increase
is proportional to the LV enlargement and, in addition to
preserved contractility, can represent an adaptive mechanism to
prevent FMR in a dilated ventricle. Further mechanistic
studies are needed to explore how we can modulate this
adaptation to prevent FMR in other diseases.
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